Hanmi Pharm

Hanmi Pharm · Pharma/GLP-1

Fri, May 8, 2026·Before Market Open

Hanmi PharmGLP-1ObesityK-BioEarnings

01Wall Street Consensus

EPS₩3,500

Revenue₩320B

02Earnings Results

EPS₩3,550.86

RevenueKRW 392.9B-1.9%

After-Hours Reaction-4.8%

Key Takeaways

Revenue was KRW 392.9B, up 0.5% YoY
Operating profit was KRW 53.6B, down 9.1% YoY
Net income was KRW 51.1B, up 14.4% YoY
Rosuzet outpatient prescription revenue rose 9.2% YoY to KRW 59.3B
Beijing Hanmi and Hanmi Fine Chemical contributed to earnings defense
R&D spending was KRW 65.2B, or 16.6% of revenue

Key Checkpoints

01Efpeglenatide (GLP-1) clinical trial progress — Phase 3 obesity and diabetes data readouts
02LAPS (Long-Acting Peptide/Protein Discovery) platform licensing deal pipeline
03Domestic pharma revenue — base business stability amid clinical investment period
04R&D spending as % of revenue — investment intensity for GLP-1 pipeline
05Global partnership revenue — milestone payments and royalty income

Upside Catalysts

Efpeglenatide differentiation: long-acting GLP-1 with potential once-monthly dosing advantage
LAPS platform: validated drug delivery technology attracting global pharma partnerships
GLP-1 market size: $100B+ by 2030 — even small market share would be transformative for Hanmi
K-Bio momentum: Korean biotech sector attracting global investor attention
Licensing deal upside: any new global partnership would provide non-dilutive funding + validation

Risk Factors

Clinical trial risk: efpeglenatide Phase 3 failure would devastate stock — binary outcome
GLP-1 competition: Lilly (tirzepatide), Novo (semaglutide), Amgen, Viking — crowded market
Funding: clinical trials require significant cash burn — potential equity raise dilution risk
Timeline uncertainty: regulatory approval even if trials succeed could take 2-3 years
KOSPI macro: small/mid-cap biotech names highly volatile in risk-off environment

Detail

SEPS 서프라이즈 히스토리

Beat1Miss0Beat률 100%

분기별 EPS 컨센서스 대비 서프라이즈(%) — 막대: EPS, 점선: 매출

컨센서스 대비 실제 EPS/매출 서프라이즈 (%)

Comments

Earnings

02Earnings Results

EPS₩3,550.86

RevenueKRW 392.9B-1.9%

After-Hours Reaction-4.8%

Key Takeaways

Revenue was KRW 392.9B, up 0.5% YoY
Operating profit was KRW 53.6B, down 9.1% YoY
Net income was KRW 51.1B, up 14.4% YoY
Rosuzet outpatient prescription revenue rose 9.2% YoY to KRW 59.3B
Beijing Hanmi and Hanmi Fine Chemical contributed to earnings defense
R&D spending was KRW 65.2B, or 16.6% of revenue

Key Checkpoints

01Efpeglenatide (GLP-1) clinical trial progress — Phase 3 obesity and diabetes data readouts

02LAPS (Long-Acting Peptide/Protein Discovery) platform licensing deal pipeline

03Domestic pharma revenue — base business stability amid clinical investment period

04R&D spending as % of revenue — investment intensity for GLP-1 pipeline

05Global partnership revenue — milestone payments and royalty income

Upside Catalysts

Efpeglenatide differentiation: long-acting GLP-1 with potential once-monthly dosing advantage

LAPS platform: validated drug delivery technology attracting global pharma partnerships

GLP-1 market size: $100B+ by 2030 — even small market share would be transformative for Hanmi

K-Bio momentum: Korean biotech sector attracting global investor attention

Licensing deal upside: any new global partnership would provide non-dilutive funding + validation

Risk Factors

Clinical trial risk: efpeglenatide Phase 3 failure would devastate stock — binary outcome

GLP-1 competition: Lilly (tirzepatide), Novo (semaglutide), Amgen, Viking — crowded market

Funding: clinical trials require significant cash burn — potential equity raise dilution risk

Timeline uncertainty: regulatory approval even if trials succeed could take 2-3 years

KOSPI macro: small/mid-cap biotech names highly volatile in risk-off environment